-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

777 Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Thrombosis: Thrombosis II
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinically Relevant, Thromboembolism, SARS-CoV-2/COVID-19, Diseases, Thrombotic Disorders, Infectious Diseases
Monday, December 13, 2021: 5:00 PM

Daria V Madeeva, MD1, Kelly Borges, MS2*, Marcus Shallow3*, Prerak V Juthani, BA4*, Stephen Y Wang, MD MPH5*, Akash Gupta, MD5*, Hyung J. Chun, MD6*, Alfred Ian Lee, MD, PhD7 and Alexander B Pine, MD PhD8

1Yale New Haven Hospital, New Haven, CT
2Yale Center for Clinical Investigation, Yale University School of Medicine, New Haven, CT
3Yale University, New Haven, CT
4Yale School of Medicine, New Haven, CT
5Department of Medicine, Yale University School of Medicine, New Haven, CT
6Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT
7Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
8Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT

BACKGROUND. COVID-19 is a prothrombotic disease, characterized by endotheliopathy, hypercoagulability, and thromboembolic complications. We hypothesized that the pathogenesis of thromboembolism associated with COVID-19 might differ from thromboembolism in patients without COVID-19. In this study, we sought to evaluate the proteomic signatures of plasma from patients with venous thromboembolism with and without COVID-19.

METHODS. Between December 17, 2020 and February 25, 2021 blood was collected from 48 hospitalized patients. Of these 24 had a confirmed diagnosis of COVID-19 infection (COVID+) and radiologic confirmation of arterial or venous thromboembolism (TE+); 17 had COVID-19 infection with absence of arterial thrombosis clinically and absence of venous thromboembolism on lower extremity Doppler ultrasound or chest CT angiography (COVID+/TE–), while 7 were arterial or venous thromboembolism in the absence of COVID-19 (COVID–/TE+). Blood was collected in sodium citrate tubes and centrifuged at 4000 rpm for 20 minutes, with resulting plasma supernatant used for protein profiling performed at Eve Technologies (Calgary, Alberta, Canada). Institutional Review Board approval was obtained for this study. Statistical analysis was performed using GraphPad Prism (v9.1, GraphPad Software, San Diego, CA) and R (v4, R Core Team). P values <0.05 were considered statistically significant. A heatmap was generated using Heatmapper (heatmapper.ca) to represent the concentrations of proteins.

RESULTS. The median age was 63 years; overall 25 (52%) were men (13 [54%] among COVID+/TE+, 11 [65%] among COVID+/TE–, and 1 [14%] among COVID–/TE+). In COVID-19 patients who developed thromboembolic events, several proteins associated with inflammation, complement activation, and hemostasis were present at higher levels than in non-COVID-19 patients who developed thromboembolic events (Fig. 1). These included complement factors C2 and C5a, pentraxin-3 (PTX-3), lipocalin-2 (LCN2), resistin (RETN), platelet endothelial cell adhesion molecule-1 (Pecam1), serum amyloid A (SAA), and tissue factor (TF). The heatmap indicates relative protein levels detected in each subject (columns) for proteins (rows) that had statistically significant differences between groups (Fig. 2). Heatmap revealed relatively lower levels of all proteins in patients with thromboembolism without COVID–19 and relatively higher levels of proteins in patients with COVID-19, and especially in ICU patients with COVID-19 and thromboembolism.

CONCLUSIONS. Thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins involved in complement activation and immunothrombotic cascades, compared to thrombotic events in the absence of COVID-19. Activation of the classical complement pathway as evidenced by a relative increase in complement factor C2 may lead to increased TF activation, reflecting more substantial endothelial damage in COVID-19 patients. Higher levels of Pecam1, SAA, LCN2, and RETN all point to increased endotheliopathy, inflammation, and tissue damage in COVID-19 compared to non-COVID-19 thrombosis. These findings may offer insights into novel therapeutic strategies to treat immunothrombotic complications of COVID-19.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH